| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.6 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |